Axsome Therapeutics AXSM Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's stock-based comp?
- Axsome Therapeutics (AXSM) reported stock-based comp of $23.44M in Q1 2026.
- How has Axsome Therapeutics's stock-based comp changed year-over-year?
- Axsome Therapeutics's stock-based comp increased by 0.6% year-over-year, from $23.31M to $23.44M.
- What is the long-term trend for Axsome Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Axsome Therapeutics's stock-based comp has grown at a 45.7% compound annual growth rate (CAGR), from $20.8M to $93.75M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- High levels may indicate aggressive talent acquisition or retention strategies but can signal shareholder dilution.
- How does stock-based comp compare across companies?
- Common in high-growth biotech and tech firms; often analyzed as a percentage of total operating expenses.